Saving LVAD Patients by Adding Intelligence to LVAD’s Using Wireless Sensing Implants: Exhibition at the ASAIO Sixty First Annual Conference

ISS Logo 4-22-15

FOR IMMEDIATE RELEASE

ISS will exhibit a practical way to add intelligence to LVAD’s at the ASAIO Sixty First Annual Conference (June 24-27, 2015) in Chicago.

Press Release Photo 6-19-15

Michigan, USA, June 19, 2015: Integrated Sensing Systems, Inc. (ISS) announced today that the company will exhibit further results of adding intelligence to current LVAD’s by using its, miniature, wireless, left-atrium, implantable, hemodynamic monitor (IHM) at the ASAIO Sixty First annual Conference in Chicago, USA (June 24-27) in Booth number 11.

ISS is currently performing a clinical study with LVAD patients, in Sweden. The exhibited results will include the case study of saving an LVAD patient by providing early warning (a sudden rise in left-atrium pressure monitored wirelessly at home) while the patient was asymptomatic and the echocardiogram test showed no sign of thrombi. The LVAD thrombosis was confirmed by subsequent intraoperative observation which resulted in exchanging the LVAD filled with thrombi. Another impressive outcome is the great match between ISS left-atrium (LA) monitoring measurements and those of echocardiogram during LVAD Ramp tests. There were significant (p<0.05, r=0.99) correlations between implant LA pressure, pump speed, LVEDD and LAD. Wireless LA pressure measurement with ISS Titan™ sensor provides a new way to regulate and monitor the optimal LVAD pump speed.

The main goal of the individualized custom treatment for many patients with chronic cardiac diseases is to maintain a fine balance between improving cardiac output, sustaining a reasonable left-heart filling pressure, and managing cardiac rhythm. Left-heart hemodynamic monitoring is a very effective tool for the management of the LVAD patients since it both clearly shows the heart rhythm and directly provides filling pressure measurements without being affected by other common pulmonary comorbidities such as pulmonary embolism. The medical management of patients with LVAD’s has added challenges due to the high risk of thrombogenic issues, such as stroke and LVAD malfunction, as well as potential for right ventricle failure. The LA pressure is of special interest when following the balance between preload of an LVAD pump and unloading of the left ventricle (LV). Monitoring the left heart is, however, very challenging due to the stringent biocompatibility and hemodynamic requirements of the left heart.

Dr. Nader Najafi, ISS President and CEO, stated that, “the early results are very promising and may lead to the use of ISS IHM implants as the standard of care for LVADs. A more advanced LVAD system consisting of two ISS sensing implants to monitor two heart chambers is under development.”

Company Background: ISS is a leader in advanced MEMS technologies for design and manufacturing of medical devices. Founded in 1995, ISS is one of the oldest independent medical MEMS companies in the United States. ISS operates a comprehensive, state-of-the-art MEMS fabrication facility located near Ann Arbor, Michigan. ISS is currently certified for ISO 9001:2008, EN13980:2002 for its ATEX (intrinsically safe products), and ISO13485:2003 standard for Class III medical devices. ISS is a vertically integrated company dedicated to developing and manufacturing system-level products based on MEMS technology (MEMS Inside), please visit: http://www.mems-iss.com/

Source: Integrated Sensing Systems, Inc. (ISS)

Contact:Nader Najafi, Ph.D.
Integrated Sensing Systems Inc. (ISS)
391 Airport Industrial Dr., Ypsilanti, MI 48198
Tel: (734) 547-9896 Ext. 103
Fax: (734) 547-9964
Email: nader@mems-iss.com

Comments are closed.